Advertisement

Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 600x60px
Document › Details

ProImmune Ltd.. (12/12/17). "Press Release: ProImmune Introduces MutaMap High-throughput Service for Mutational Activity Maps of Therapeutic Proteins". Oxford.

Organisations Organisation ProImmune Ltd.
  Group ProImmune (Group)
  Organisation 2 Zyme Communications Ltd.
Products Product MutaMap™ high-througput proteomic assay service
  Product 2 research test, proteomic / protein
Person Person Jeffery, Sarah (Zyme Communications 201504)
     


Next generation protein engineering technology for improved drug candidate decision making


ProImmune, a leader in services for understanding immune responses, today announced the introduction of MutaMap™, a new high-throughput assay service for understanding the impact of point mutations on protein therapeutic activity, including monoclonal antibodies. MutaMap provides a high-throughput service, with high-quality output data, to help decide which individual point mutations to pursue and enable better protein engineering decisions to be made, prior to committing a drug candidate to a clinical program.

MutaMap is an in vitro assay system that explores the effect of deliberate point mutations on protein activity by substituting each of the 19 possible amino acid alternatives in each position in a protein sequence, one by one. Each position of a protein of interest is altered by site-directed mutagenesis, expressed and changes in affinity or activity measured using cell-free in vitro translation of proteins and solution titration assays. These methods avoid the use of surrogate measurements for affinity or activity and have been optimized for high-throughput processing of samples without compromising on readout accuracy. The technology is particularly suited for investigating a range of the ligand-binding interactions, from high-affinity monoclonal antibodies down to the high-femtomolar range where other approaches, such as surface plasmon resonance (SPR), struggle to deliver results in high throughput.

MutaMap can deliver a high-throughput mutagenesis project for exploring 500-2000 mutations in approximately 8-12 weeks and deliver a heat map for the protein sequence of interest, showing which point mutations lead to an increase, decrease, or no change in affinity (or other activity), or non-function of the protein of interest when interacting with one, or more, of its binding partners. This effectively reveals which mutations are likely permissible or favourable for protein engineering and provides a novel tool for making informed decisions across a range of key developability objectives. These can include cherry picking mutations to improve activity, de-immunization, altering cross-species reactivity, improved humanization or provision of other engineered features, stability and manufacturability, prolonging half-life and developing unique new composition of matter IP.

MutaMap is the first service ProImmune is offering in the area of protein engineering. The technology is complementary to the company’s existing technologies for assessing the antigenicity of therapeutic proteins and can be readily combined with ProImmune’s leading ProMap® and ProScern® T cell assays, ProPresent® Antigen Presentation Assays and ProImmune REVEAL® MHC-peptide binding assays.

Nikolai Schwabe, CEO of ProImmune commented: “MutaMap is a key new service in our portfolio that addresses a major unmet need for our customers to make informed protein engineering decisions on a broad range of developability issues such as managing the immunogenicity risk of therapeutic proteins, with confidence that the function of the candidate protein will be maintained or even be improved.”

For further information visit www.proimmune.com.


ENDS


Notes to Editors:


About ProImmune - www.proimmune.com

ProImmune offers unique solutions for immunology research and biologics drug development through integrated systems for antigen characterization, immunogenicity testing, immune monitoring and protein developability engineering. ProImmune is committed to helping its partners achieve success by offering novel industry leading technologies for developing better therapies faster.

For more information, please contact

At ProImmune:

Jeremy Fry
Tel: +44 (0) 870 042 7279
Email: enquiries@proimmune.com

Media enquiries:

Sarah Jeffery
Zyme Communications Ltd
Tel: +44 (0) 7771 730 919
Email: sarah.jeffery@zymecommunications.com







[ als ZUSATZINFO geholt via http://www.proimmune.com/ecommerce/page.php?page=Contact-Us ; ML ]


http://www.proimmune.com/ecommerce/page.php?page=Contact-Us


United Kingdom
ProImmune Ltd.

Address:

The Magdalen Centre,
Oxford Science Park,
Oxford, OX4 4GA, UK

Telephone: +44 870 042 7279
Fax: +44 870 712 0588
Email: enquiries@proimmune.com

USA
ProImmune Inc.

Address:

4281 Express Lane,
Suite L2378,
Sarasota, FL 34249-2602, USA

Telephone: +1 888 505 7765
Fax: +1 775 206 4635
Email: enquiries@proimmune.com


Head office, Registered in England
Company No. 387 33 86, VAT Reg. No. 749 90 53 87



http://www.proimmune.com/ecommerce/page.php?page=About-Us


Mastering Immunity

ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen characterization platform, and products and services for tracking antigen-specific immune responses with state-of-the-art ELISpot and flow cytometry techniques. We are committed to helping you take your studies to success through product innovation, responsive service and focused application support, saving you time and money and reducing risk.

The Story of ProImmune...

The study of immunology isn’t only relevant to illness. Every foreign agent that enters the body has the potential to provoke a response from the immune system. Usually, this keeps us disease-free, as ‘self’ is tolerated and ‘non-self’ attacked and eliminated. When ‘self’ is mistakenly attacked, we see the development of autoimmune disease, and when ‘non-self’ gets the upper hand we fall prey to acute or chronic infections.

Everyone from medical researchers to household brands needs to know exactly which substances can stimulate the immune system, and which substances can sneak under the radar. Portions of substances that the immune system can recognise are called epitopes, and identifying potential epitopes and monitoring the immune response to them is where ProImmune has become a world leader.

Dr. Linda Tan & Dr. Nikolai Schwabe

Dr. Linda Tan & Dr. Nikolai Schwabe


Dr Linda Tan and Dr Nikolai Schwabe founded ProImmune in 2000. The business has never relied on outside investment, and this independence from external investors continues to allow ProImmune to pursue its own business direction. The company developed building on Linda’s PhD work at Oxford's Weatherall Institute of Molecular Medicine.

Among ProImmune’s early products were Pro5® MHC Pentamers, which are used to detect epitope-specific immune cells so that they can be analyzed in human blood samples. Pentamers as well as ProT2® MHC Class II Tetramers introduced in 2016 continue to be part of ProImmune’s core business and have gone from strength to strength with more than 1400 peer reviewed publications citing the use of these products.

ProImmune has pro-actively maintained links with its academic roots and contributed to diverse collaborative projects over the years. The company’s motto ‘Mastering Immunity’ reflects the importance to medical science of understanding how the immune system functions.

Company Directors


Dr Nikolai Schwabe, CEO

Prior to co-founding ProImmune with Linda Tan, Nik worked in the fiber optics industry at Bookham Technology and in investment banking at Salomon Brothers, now part of Citigroup. Nik holds a D.Phil. in Theoretical Physics from Oxford University.

Dr Linda Tan, CSO

Before co-founding ProImmune with Nik Schwabe, Linda completed her D.Phil. at the Institute of Molecular Medicine at Oxford in the laboratory of Prof. Andrew McMichael where her work focused on T cell immunology and the MHC pathway. Linda holds a D.Phil. in Molecular Immunology and a B.A. in Biochemistry, both from Oxford University.

   
Record changed: 2017-12-22

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 600x80px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px